Pantothenic Acid for Health & Longevity - Quick Reference Sheet

Pantothenic Acid for Health & Longevity

Created on 08/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

An essential vitamin present in nearly all foods, so shortage on mixed diets is close to unknown. Cells cap their own production once supply is plentiful, which appears to be why large doses fail to raise levels in muscle. The clearest effects come from a related compound that modestly lowers blood fats. Safety is favorable; much cholesterol research was industry-funded. (Full Review)

Protocol

Integrative lipid approach with pantethine
600 → 900 mg/day
600 mg/day for 8 weeks, then 900 mg/day in three doses with meals
Acne protocol
2.2 g/day
Two tablets twice daily with food for 12 weeks
Nutritional baseline
5 mg/day
Adequate Intake for adults; mixed diets deliver 4-7 mg/day
Time to effect
Deficiency correction
Days to weeks
Symptom resolution, only where intake is genuinely inadequate
Lipids
4-16 weeks
Changes appear by week 4, complete by week 16
Acne
12 weeks
Lesion counts need the full 12 weeks

Benefits

Contraindications
  • Delayed-type (Type IV) hypersensitivity to panthenol, dexpanthenol, or calcium pantothenate confirmed on patch testing
  • Unexplained eosinophilia above 1,500 cells/mm³, or unexplained pleural or pericardial effusion within the past 90 days, until the cause is established
  • No other population identified; no absolute contraindication in healthy adults
Key Interactions
  • Prescription drugs - tetracyclines and fluoroquinolones: Reduced absorption of doxycycline, minocycline, ciprofloxacin, levofloxacin
  • Prescription drugs - lipid-lowering agents: Additive with statins (atorvastatin, rosuvastatin), ezetimibe, fibrates (fenofibrate)
  • Prescription drugs - cholinesterase inhibitors: Donepezil, rivastigmine, galantamine (theoretical caution)
  • Over-the-counter medications: None clinically significant with analgesics, antihistamines, antacids
  • Supplement interactions - biotin and alpha-lipoic acid: Gram-level doses may reduce their uptake
  • Supplements with additive effects: Red yeast rice, plant sterols, berberine, soluble fiber, marine omega-3s
  • Antiplatelet and anticoagulant agents: Altered platelet aggregation (aspirin, clopidogrel, apixaban, high-dose fish oil, ginkgo)
  • Other intervention interactions: Immune checkpoint inhibitors under study (investigational only)

Risk & Side Effects

  • High: Gastrointestinal upset and loose stools at multi-gram doses
  • Medium: Under-treated apolipoprotein B when pantethine substitutes for proven therapy
  • Low: Allergic contact dermatitis; competition with biotin and lipoic acid for the shared transporter
  • Speculative: Eosinophilic pleuropericardial effusion; autophagy suppression; support of tumor metabolism

Monitoring

Marker Target Why
Apolipoprotein B 60-80 mg/dL Best single count of artery-damaging particles
LDL cholesterol Below 70-100 mg/dL Primary endpoint of both pantethine trials
Triglycerides Below 100 mg/dL The lipid fraction pantethine moves most
Whole-blood pantothenic acid 1.6-2.7 µmol/L Only direct measure of vitamin status
Urinary pantothenic acid Above 1 mg per 24 hours Reflects recent intake where no blood assay is available
Alanine aminotransferase 10-26 U/L Safety check during gram-level dosing
Complete blood count Change from own baseline (eosinophils) Safety endpoint used in the acne trial
High-sensitivity C-reactive protein Below 1.0 mg/L Context for cardiovascular risk when lipids change

Cadence: Baseline, then lipid panel at 8 and 16 weeks and every 6-12 months thereafter; for acne, lesion count and liver enzymes at 12 weeks

Qualitative Assessment

  • Stool consistency and frequency, the earliest signal that dose has exceeded absorption
  • Lesion count and skin comfort, photographed monthly under fixed lighting if acne is the target
  • Duration of morning joint stiffness in minutes, if inflammatory joint symptoms are the target
  • Skin hydration and irritation at any site where topical panthenol is applied
  • Energy and cognitive clarity, against the expectation that no controlled trial has found a change